Our findings provide some support for these recommendations by suggesting that combination therapy with an SGLT2 inhibitor and a GLP-1 RA may further reduce cardiorenal risk in individuals with type 2 diabetes in real-world practice without a clear increase in the risk of specific adverse events such as hypoglycaemia, ketoacidosis and genitourinary tract infections. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.